Saturday, November 23, 2024
HomeTagsDF6002

DF6002

Dragonfly Therapeutics Announces the Publication of Preclinical Data Supporting DF6002, its Extended Half-life IL-12 Cytokine, as A Promising Treatment for Cancer

Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, announced the April 13th publication of preclinical data in Cell Press's Med supporting DF6002...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics